Waaree Energies approves amalgamation of Indosolar to consolidate solar manufacturing
As filed · Waaree Energies Limited has informed the Exchange about Scheme of Amalgamation of Indosolar Limited with Waaree Energies Limited and their respective shareholders pursuant to Sections 230 to 232 of th
What happened
FactWaaree Energies’ board approved a draft scheme to amalgamate Indosolar Limited into Waaree Energies, subject to stock exchange, tribunal, shareholder and creditor approvals. The companies are related parties, and the filing states the consideration will be discharged on an arm’s-length basis.
Why it matters
CapitSignal interpretationA merger fixes a share-exchange ratio, which permanently sets how much of the combined company existing holders own.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Demand
Delayedthe way things are happening on the data center side, hopefully, it should add -- and this is a guess estimate, 15 gigawatt to 20 gigawatt of additional solar and BESS demand driven by data center.
Q1FY27 Revenue Surges to ₹7,931.79 Crores, Growth of 79.22% YoY
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Swap ratio and its valuation basis
- Regulatory and NCLT approvals required
- Appointed date
- We remain confident in our long-term growth trajectory and reaffirm our FY27 Operating EBITDA guidance of ₹7,0 (management committed by FY27)
- 10 GW Cell facility at Unn, Gujarat is progressing as per plan & expected to start production in current finan (management committed by FY27)
Evidence
- Waaree Energies Limited has informed the Exchange regarding Outcome of Board Meeting held on Wednesday, September 23, 2026.(opens the original filing in a new tab)
- Earlier statement · Q1 FY27
- Latest statement · Q1 FY27
- Earlier statement · Q4 FY26
How CapitSignal classified this
- Reasoning:
- The proposed merger would place Indosolar’s module manufacturing alongside Waaree’s cell and module operations, potentially improving production planning and reducing dependence on external cell supplies. Completion remains contingent on statutory, regulatory and customary approvals.
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%